Remibrutinib Improves Chronic Spontaneous Urticaria in Patients Irrespective of Previous Anti-IgE Treatment: Results From a Phase 2b Study

被引：0
|
作者：
Greiner, Alexander [1 ,2 ]
Guduri, Sridhar [3 ]
Leflein, Jeffrey [4 ]
Haemmerle, Sibylle [5 ]
Lheritier, Karine [5 ]
Walsh, Pauline [6 ]
Nikolaev, Ivan [5 ]
Gimenez-Arnau, Ana [7 ]
Maurer, Marcus [8 ]
机构：
[1] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA
[2] Univ Calif San Diego, San Diego, CA USA
[3] Centricity Res Inc, Columbus, OH USA
[4] Resp Med Res Inst Michigan, Ann Arbor, MI USA
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Ireland Ltd, Dublin, Ireland
[7] Univ Pompeu Fabra, Hosp Mar IMIM, Barcelona, Spain
[8] Charit Univ Med Berlin, Urticaria Ctr Reference & Excellence UCARE, Berlin, Germany
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2023年 / 151卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
404
引用
收藏
页码：AB131 / AB131
页数：1
相关论文
共 50 条
  • [31] Setrusumab for the Treatment of Osteogenesis Imperfecta (OI): Results from the Phase 2b ASTEROID Study
    Glorieux, Francis
    Javaid, Muhammad K.
    Langdahl, Bente
    Chapurlat, Roland
    De Beur, Suzanne Jan
    Sutton, V. Reid
    Poole, Kenneth
    Orwoll, Eric S.
    Willie, Bettina
    Mikolajewicz, Nicholas
    Clancy, James
    MacKinnon, Alastair
    Mistry, Arun
    Ominsky, Michael S.
    Saville, Chris
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 5 - 6
  • [32] Safety and tolerability of omalizumab in patients with chronic idiopathic/spontaneous urticaria: Results from the OPTIMA study
    Sussman, Gordon
    Hebert, Jacques
    Gooderham, Melinda
    Gulliver, Wayne
    Lynde, Charles W.
    Papp, Kim A.
    Yang, William H.
    de Takacsy, Frederica
    Chambenoit, Olivier
    Rihakova, Lenka
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB250 - AB250
  • [33] Patients' Experience of Parkinson's Disease Following Treatment with Inhaled Levodopa: Results from a Phase 2b Study
    LeWitt, Peter
    Niyazov, Alexander
    Sedkov, Alexander
    Murck, Harald
    Guo, Amy
    NEUROLOGY, 2016, 86
  • [34] Complete freedom from chronic spontaneous urticaria signs and symptoms is associated with sleep and dermatology quality-of-life improvements: Data from the phase 2b ligelizumab study
    Bernstein, Jonathan A.
    Gimenez-Arnau, Ana
    Hide, Michihiro
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB35 - AB35
  • [35] Effect of Linaclotide On Quality of Life in Adults with Chronic Constipation: Results from a Phase 2B Study
    Lavins, Bernard J.
    Johnston, Jeffrey M.
    MacDougall, James E.
    Lembo, Anthony J.
    Schneier, Harvey
    Shiff, Steven J.
    Carson, Robyn T.
    Kurtz, Caroline B.
    Currie, Mark G.
    GASTROENTEROLOGY, 2009, 136 (05) : A71 - A71
  • [36] Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study
    Ben-Shoshan, Moshe
    Sekerel, Bulent Enis
    Staubach-Renz, Petra
    Alvaro-Lozano, Montserrat
    Maurer, Marcus
    Drollmann, Anton
    Bienczak, Andrzej
    Porter, Miriam
    Liu, Tian
    Burciu, Alis
    Severin, Thomas
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB179 - AB179
  • [37] Differentiation between control subjects and patients with chronic spontaneous urticaria based on the ability of anti-IgE autoantibodies (AAbs) to induce FcεRI crosslinking, as compared to anti-FcεRIα AAbs
    Izaki, Satoshi
    Toyoshima, Shota
    Endo, Takahiro
    Kanegae, Kazuko
    Nunomura, Satoshi
    Kashiwakura, Jun-ichi
    Sasaki-Sakamoto, Tomomi
    Nakamura, Ryosuke
    Akiyama, Haruyo
    Ra, Chisei
    Hayama, Koremasa
    Terui, Tadashi
    Okayama, Yoshimichi
    ALLERGOLOGY INTERNATIONAL, 2019, 68 (03) : 342 - 351
  • [38] Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: Primary results of a placebo- and active-controlled phase 2b dose finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    ALLERGY, 2018, 73 : 837 - 837
  • [39] Initial results from BEACON, a phase 1b/2a dose escalation study of the anti-c-Kit briquilimab antibody in adults with chronic spontaneous urticaria (CSU)
    Casale, Thomas
    Tucker, Edwin
    Yuan, Jinwei
    Adelman, Daniel
    Ku, David
    Marcantonio, Annette
    Carlos, Patricia
    Majeed, Sophia
    Pang, Wendy
    Maurer, Marcus
    Metz, Martin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB435 - AB435
  • [40] Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: results from the X-ACT study
    Weller, K.
    Staubach, P.
    Metz, M.
    Chapman-Rothe, N.
    Sieder, C.
    Braeutigam, M.
    Maurer, M.
    ALLERGY, 2017, 72 : 96 - 96
12345